Syndax Pharmaceuticals Inc Stock Price, News & Analysis

Syndax Pharmaceuticals (NASDAQ: SNDX) has appointed Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer. Dr. Botwood brings over 25 years of industry experience, most recently serving as Head of Worldwide Medical Oncology at Bristol Myers Squibb. He succeeds Dr. Neil Gallagher, who is departing the company.

Dr. Botwood's extensive background includes senior roles at BMS from 2015-2025, where he oversaw medical activities in oncology, including new asset launches and commercial strategy. Previously, he held leadership positions at AstraZeneca from 2003-2015. His appointment comes as Syndax continues to expand its oncology portfolio, including the recent submission of Revuforj supplemental New Drug Application for relapsed or refractory mNPM1 acute myeloid leukemia.

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on innovative cancer therapies, has announced its participation in two upcoming investor conferences in May 2025. CEO Michael A. Metzger and the management team will present at:

- The Bank of America Merrill Lynch Vegas Health Care Conference on May 15, 2025, at 12:20 p.m. ET

- The TD Cowen 6th Annual Oncology Innovation Summit on May 28, 2025, at 10:30 a.m. ET

Both presentations will be available via webcast on the company's website at www.syndax.com.

Syndax Pharmaceuticals (NASDAQ: SNDX) announced the publication of pivotal Phase 2 data for revumenib in the journal Blood, showing promising results in treating relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia (AML). The study demonstrated a nearly 50% overall response rate in heavily pre-treated patients.

The company submitted a supplemental New Drug Application (sNDA) for revumenib in R/R mNPM1 AML in April 2025 under the FDA's Real-Time Oncology Review program. This follows revumenib's FDA approval as Revuforj® in November 2024 for treating R/R acute leukemia with KMT2A translocation in patients one year and older.

Syndax Pharmaceuticals reported strong Q1 2025 financial results, highlighting successful product launches. Revuforj generated $20.0 million in net revenue in its first full quarter, while Niktimvo achieved $13.6 million in net revenue in its partial first quarter. The company submitted an sNDA for Revuforj in R/R mNPM1 AML and initiated a pivotal frontline trial combining Revuforj with venetoclax and azacitidine. Multiple ongoing trials are evaluating both drugs across various indications. Q1 2025 showed increased R&D expenses of $61.6 million and SG&A expenses of $41.0 million. The company reported a net loss of $84.8 million ($0.98 per share). With $602.1 million in cash and investments, Syndax expects to reach profitability through current resources and anticipated product revenue.

Syndax Pharmaceuticals (SNDX) has granted inducement awards to seven new employees under its 2023 Inducement Plan. The awards consist of options to purchase up to 188,100 shares of common stock. The stock options have a four-year vesting schedule, with 25% of shares vesting after one year and the remaining 1/48th vesting monthly over the subsequent 36 months, contingent on continued employment with Syndax.

Syndax Pharmaceuticals (SNDX) has scheduled its first quarter 2025 financial results announcement and business update for Monday, May 5, 2025. The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day.

Investors and interested parties can access the webcast through the Events & Presentations page in the Investors section of Syndax's website. Alternative access is available via phone using the Conference ID: Syndax1Q25, with domestic dial-in at 800-590-8290 and international at 240-690-8800.

A replay of the conference call will be available on the company's website approximately 24 hours after the event and will remain accessible for 90 days.

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced inducement grants under NASDAQ Listing Rule 5635(c)(4). The company granted stock options to purchase up to 50,000 shares of common stock to four new employees under its 2023 Inducement Plan.

The stock options feature a four-year vesting schedule, with 25% of shares vesting after the first year and the remaining shares vesting monthly at 1/48th over the subsequent 36 months. Continued employment with Syndax is required through applicable vesting dates.

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced its upcoming participation in the Stifel 2025 Virtual Targeted Oncology Forum. CEO Michael A. Metzger and other management team members will engage in a fireside chat scheduled for Wednesday, April 9, 2025, at 10:30 a.m. ET. The event will be accessible via live webcast through the company's website investor section, with a replay option available for a time.

Syndax Pharmaceuticals (NASDAQ: SNDX) has announced the granting of inducement awards under its 2023 Inducement Plan. The company, which focuses on developing cancer therapies, issued stock options to purchase up to 282,000 shares of common stock to 12 new employees on March 1, 2025.

The stock options feature a four-year vesting schedule, with 25% of shares vesting after the first year, followed by monthly vesting of 1/48th of the underlying shares over the subsequent 36 months. Continued employment with Syndax is required through the applicable vesting dates.